[Plasma resistin level in obstructive sleep apnea hypopnea syndrome]

Area of Science:

• Endocrinology
• Sleep Medicine
• Biochemistry

Context:

• Obstructive sleep apnea hypopnea syndrome (OSAHS) is associated with metabolic disturbances.
• Resistin, an adipokine, plays a role in insulin resistance and inflammation.
• Understanding resistin's role in OSAHS is crucial for managing associated comorbidities.

Purpose:

• To investigate plasma resistin levels in obese patients with OSAHS.
• To determine the correlation between resistin levels and OSAHS severity (AHI).
• To explore the clinical implications of elevated resistin in OSAHS.

Summary:

• Plasma resistin levels were significantly higher in obese OSAHS patients compared to obese controls and healthy individuals.
• Resistin levels positively correlated with BMI, various anthropometric measures, metabolic markers, and crucially, the apnea-hypopnea index (AHI).
• The apnea-hypopnea index (AHI) emerged as the most significant predictor of elevated plasma resistin in obese OSAHS patients.

Impact:

• Elevated plasma resistin is linked to OSAHS severity.
• Resistin may serve as a valuable biomarker for assessing OSAHS progression and metabolic impact.
• Findings highlight potential therapeutic targets related to resistin in OSAHS management.